Year in Review | Published:

LUNG CANCER IN 2018

A banner year for immunotherapy and targeted therapy

Nature Reviews Clinical Oncologyvolume 16pages7980 (2019) | Download Citation

In 2018, advances in the treatment of non-small-cell lung cancer (NSCLC) have been observed both in trials of immunotherapies and targeted agents, leading to dramatically improved options for patients with metastatic and stage III NSCLC.

Key advances

  • Combination of immune-checkpoint inhibitors (ICI) with chemotherapy extends survival regardless of PD-L1 expression4,5.

  • New-generation targeted agents improve outcomes for patients with EGFR or ALK-driven disease8,9.

  • Patients with unresectable stage III NSCLC can benefit from consolidation therapy with durvalumab following chemoradiation11.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2016).

  2. 2.

    Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).

  3. 3.

    Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).

  4. 4.

    Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).

  5. 5.

    Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1810865 (2018).

  6. 6.

    Jotte, R. M. et al. IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel versus carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC [abstract]. J. Clin. Oncol. 36 (Suppl. 18), LBA9000 (2018).

  7. 7.

    Mok, T. S. et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376, 629–640 (2017).

  8. 8.

    Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).

  9. 9.

    Camidge, D. R. et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1810171 (2018).

  10. 10.

    Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919–1929 (2017).

  11. 11.

    Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1809697 (2018).

Download references

Author information

Affiliations

  1. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA

    • Jennifer W. Carlisle
    •  & Suresh S. Ramalingam

Authors

  1. Search for Jennifer W. Carlisle in:

  2. Search for Suresh S. Ramalingam in:

Competing interests

S.S.R. has served as a consultant for Abbvie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Lilly Oncology, Loxo, Merck, Nektar, Roche and Tesaro; has received travel support to attend advisory board meetings from AstraZeneca, EMD Serono and Pfizer; and his institution receives research support from Abbvie, AstraZeneca, Bristol Myers Squib, EMB Serono, Pfizer, Takeda and Vertex. J.W.C. declares no competing interests.

Corresponding author

Correspondence to Suresh S. Ramalingam.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41571-018-0138-4

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing